Immunology News and Research RSS Feed - Immunology News and Research

Immunology is the study of the body's immune system.
UTMB scientists develop quick-acting vaccine that is effective against Ebola strain

UTMB scientists develop quick-acting vaccine that is effective against Ebola strain

An interdisciplinary team from The University of Texas Medical Branch at Galveston and Profectus BioSciences, Inc. has developed a quick-acting vaccine that is both safe and effective with a single dose against the Ebola strain that killed thousands of people in West Africa last year. [More]
New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that clinical data for simeprevir, its NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver taking place in Vienna from April 22-26. [More]
Researchers reveal molecular structure of cytotoxin from Mycoplasma pneumoniae

Researchers reveal molecular structure of cytotoxin from Mycoplasma pneumoniae

Researchers from the School of Medicine at The University of Texas Health Science Center at San Antonio today revealed the molecular structure of the cytotoxin from Mycoplasma pneumoniae, a widespread, highly contagious bacterium that infects the lungs. [More]
Study identifies gut immune system as new, effective target for diabetes

Study identifies gut immune system as new, effective target for diabetes

A commonly-used drug to treat inflammatory bowel disease, such as Crohn's disease, has been shown to lower blood sugar levels in obese mice, potentially identifying the gut immune system as a new and effective target in treating diabetes in humans. [More]
CXCR3 molecule is key mediator of melanoma metastasis, shows research

CXCR3 molecule is key mediator of melanoma metastasis, shows research

In a unique partnership demonstrating excellence in "team science," Dartmouth investigators from Norris Cotton Cancer Center identified a role for the molecule CXCR3 (widely known to regulate the migration of immune cells) as a key mediator of melanoma metastasis. [More]
Common cancers deform mitochondria to create conducive environment for tumor growth

Common cancers deform mitochondria to create conducive environment for tumor growth

In a breakthrough in the understanding of how cancer does its deadly work, researchers at the University of Virginia School of Medicine have shown that many cancers - including nearly all pancreatic cancers - enslave and deform mitochondria, the powerhouses of cells, to create an environment more conducive to tumor growth. [More]
MGH investigators identify inflammatory molecule that plays key role in lupus

MGH investigators identify inflammatory molecule that plays key role in lupus

Massachusetts General Hospital (MGH) investigators have identified an inflammatory molecule that appears to play an essential role in the autoimmune disorder systemic lupus erythematosus, commonly known as lupus. [More]
Scientists identify rhinovirus C receptor associated with severe asthma attacks

Scientists identify rhinovirus C receptor associated with severe asthma attacks

Scientists funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have identified a cellular receptor for rhinovirus C, a cold-causing virus that is strongly associated with severe asthma attacks. [More]
Findings of Ariosa's non-invasive prenatal testing study published online in NEJM

Findings of Ariosa's non-invasive prenatal testing study published online in NEJM

Results from the largest clinical trial to date, comparing non-invasive prenatal testing (NIPT) using the Harmony Prenatal Test with conventional first trimester combined screening (FTS) in a general pregnancy population have been published online in The New England Journal of Medicine. [More]
Personalized cancer vaccines can be used to marshal powerful immune response

Personalized cancer vaccines can be used to marshal powerful immune response

Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis. [More]
Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML). [More]
Biotest Pharmaceuticals relocates its plasma collection center to San Antonio, Texas

Biotest Pharmaceuticals relocates its plasma collection center to San Antonio, Texas

Biotest Pharmaceuticals Corporation (BPC), a leading developer of immunology biotherapeutic products, is pleased to announce the relocation of its plasma collection center to 618 NW Loop 410 Suite 101 San Antonio, Texas. [More]
NASH patients more likely to have increased intestinal permeability, shows study

NASH patients more likely to have increased intestinal permeability, shows study

Non-alcoholic steatohepatitis (NASH), the more severe form of non-alcoholic fatty liver disease (NAFLD) that can progress to liver fibrosis and cirrhosis, is associated with leakiness of the intestinal wall, which in turn may worsen liver disease, according to research published in Cellular and Molecular Gastroenterology and Hepatology, the new basic science journal of the American Gastroenterological Association. [More]
VSV-based vaccine yields promising results for rapid development of effective Ebola vaccine

VSV-based vaccine yields promising results for rapid development of effective Ebola vaccine

A live vaccine based on the "Vesicular Stomatitis Virus" (VSV) has yielded highly promising results for the rapid development of an effective vaccine against the Ebola virus. This vaccine would only need to be injected once for long-lasting immunoprotection. [More]
Low doses of imatinib drug can push immune system to combat bacterial infections

Low doses of imatinib drug can push immune system to combat bacterial infections

Low doses of the anti-cancer drug imatinib can spur the bone marrow to produce more innate immune cells to fight against bacterial infections, Emory researchers have found. [More]
New blood test promises to detect food allergies

New blood test promises to detect food allergies

A new blood test promises to predict which people will have severe allergic reactions to foods according to a new study led by Mount Sinai researchers and published online today in the The Annals of Allergy, Asthma & Immunology. [More]
Roche launches new protein melting application for real-time PCR LightCycler 1536 instrument

Roche launches new protein melting application for real-time PCR LightCycler 1536 instrument

Roche announced today the introduction of a new protein melting application for its high-throughput, real-time PCR LightCycler 1536 instrument. The fully automated platform now allows life science researchers to perform thermal shift assays (TSAs) in 1536-well applications quickly and consistently. [More]
Study finds link between neurodegenerative disorders and inflammation

Study finds link between neurodegenerative disorders and inflammation

Researchers from McMaster University and the Icahn School of Medicine at Mount Sinai, New York have discovered that a protein associated with neurodegenerative diseases like ALS also plays an important role in the body's natural antiviral response. [More]
Merck Serono, Intrexon partner to develop and commercialize CAR-T cancer therapies

Merck Serono, Intrexon partner to develop and commercialize CAR-T cancer therapies

Merck Serono, the biopharmaceutical business of Merck, and Intrexon Corporation, today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. [More]
New faculty members join UNC Lineberger to help launch immunotherapy clinical trials

New faculty members join UNC Lineberger to help launch immunotherapy clinical trials

Two new faculty members have joined the UNC Lineberger Comprehensive Cancer Center to help launch groundbreaking immunotherapy clinical trials testing an experimental treatment in which patients' own immune cells are genetically engineered to fight their cancer. [More]
Advertisement
Advertisement